Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 8 news outlets
twitter: 10 X users

patent: 1 patent

Citations

dimensions_citation: 90 Dimensions

Readers on

mendeley: 99 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 17 X posts from 10 X users, with an upper bound of 33,633 followers.

It's hard to find data showing preferential OV replication in tumour cells in vivo, the only data I've been able to find is this graph from this mouse study: https://t.co/YOe7VoyXq2 https://t.co/wqP3XzgMfF

10 Jun 2023

Reply Repost Favourite

La propuesta de desarrollar la inmunoterapia oncolitica, usando IVM para convertir las lesiones oncoligicas frías en calientes. Solo llego a eso. Convertirlas en calientes y el herpes y otras lesiones a la resina del Aciclovir. https://t.co/wQ0VRgqNYf

01 Jul 2022

Reply Repost Favourite

RT @sitcancer: #JITC Research: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 h…

05 Sep 2019

Reply Repost Favourite

#JITC Research: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 https://t.co/ng1pGana7V https://t.co/uzubLoetw7

05 Sep 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 13 additional X posts.